On July 5, the American Society for Biochemistry and Molecular Biology raised concerns regarding proposed changes to the National Institutes of Health “Grants Policy Statement.”
Sarepta faces lower revenue for Duchenne gene therapy ahead of expected sales jump with expanded treatment label
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS